



For Immediate Release

H&T Corporation
2-20-4 Morikawachi-nishi, Higashi-Osaka City, Osaka 577-0061 JAPAN
TEL: 81-6-6785-3322 / FAX: 81-6-6785-3435
Email: handt@ht21.co.jp Website: <http://www.ht21.co.jp/>

H & T Receives Investment of 48 Million Yen from NIF SMBC Ventures Co., Ltd.

(April 15, 2008 - Osaka, Japan) – H&T Corporation announced today that it had received an investment of 48 million yen from NIFSMBC Ventures Co., Ltd. (Tokyo, Japan). According to H&T, this investment has raised the Company's equity capital from 155 million yen to 181.8 million yen, and pushed the Company's reserve capital fund up to 124.8 million yen. H&T says that it plans to use the money from this investment to accelerate the development of the Company's preclinical data collection software package, TOX-LAUNCHER.

H&T's TOX-LAUNCHER system is currently three-fifths complete, with Japanese language versions of the Pathology, Weight Measurement, and Clinical Pathology subsystems all available for purchase. The remaining two subsystems, the Clinical Observation subsystem and the Reproductive Toxicity Test subsystem, are still under development, but H&T is planning to hasten the completion of these two subsystems following this most recent boost in capital.

Sold as packaged software and compliant with both Good Laboratory Practice (GLP) and FDA21 CFR Part 11 regulations, the TOX-LAUNCHER system has received high praise from a number of companies already using one or more of the three completed subsystems. Features such as Auto-Validation and H&T's selectable interface & component system have made TOX-LAUNCHER a popular choice among Japanese companies and institutions administering preclinical pharmaceutical trials. H&T is hoping to build on this success and increase its market share with the release of the final two TOX-LAUNCHER subsystems.

About H&T: The H&T Corporation was founded in 1998 and is dedicated to providing useful technologies for the benefit of both people and the environment through the Company's knowledge of medical information systems, network construction, and software engineering. H&T's main product is the TOX-LAUNCHER system, a preclinical data collection software package that aims to simplify and expedite the drug development process. Other products and services offered by H&T include the Company's Simple Series software (Simple Input and Simple Counter), as well as consulting and support services related to the administration of preclinical trials.

Additional information about H&T can be found at <http://www.ht21.co.jp/english/enews/hotnews.html>.